Provided by Tiger Trade Technology Pte. Ltd.

Belite Bio, Inc.

175.07
-8.0900-4.42%
Post-market: 175.070.00000.00%19:30 EDT
Volume:211.08K
Turnover:37.20M
Market Cap:7.05B
PE:-63.94
High:181.23
Open:180.27
Low:173.00
Close:183.16
52wk High:200.00
52wk Low:64.80
Shares:40.27M
Float Shares:19.38M
Volume Ratio:0.54
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7382
EPS(LYR):-2.3141
ROE:-22.10%
ROA:-15.65%
PB:9.08
PE(LYR):-75.65

Loading ...

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
May 20

Belite Bio Q1 Adjusted EPS USD -0.34

THOMSON REUTERS
·
May 20

Belite Bio Q1 Pretax Profit USD -26.938 Million

THOMSON REUTERS
·
May 20

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 20

Belite Bio Says Swiss Regulator Granted Orphan Drug Status to Tinlarebant to Treat Eye Disease

MT Newswires Live
·
May 19

Belite Bio receives orphan drug status for tinlarebant in Switzerland

TIPRANKS
·
May 19

Belite Bio Inc - Swissmedic Grants Orphan Drug Status to Tinlarebant for Stargardt Disease

THOMSON REUTERS
·
May 19

Swissmedic grants Belite Bio tinlarebant orphan drug status for Stargardt disease

Reuters
·
May 19

Belite Bio Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters
·
May 18

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 18

Belite Bio to present Phase 3 DRAGON tinlarebant data at Retina China symposium

Reuters
·
May 15

Belite Bio Announces Oral Presentation at the 27TH Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

THOMSON REUTERS
·
May 15

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

GlobeNewswire
·
May 15

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 15

Belite Bio to webcast first-quarter results, business update

Reuters
·
May 14

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

GlobeNewswire
·
May 14

Belite Bio CSO Nathan L. Mata disposes 666 shares worth $102,274.53

Reuters
·
May 09

Belite Bio CSO Nathan L. Mata reports disposal of shares worth $153,957.36

Reuters
·
May 08

Belite Bio CSO Nathan L. Mata sells shares worth $155,707.57

Reuters
·
May 06

Belite Bio CSO Nathan L. Mata disposes of shares worth $156,299.79

Reuters
·
May 05